Literature DB >> 1806938

A random walk through a cannabis field.

R Mechoulam1, W A Devane, A Breuer, J Zahalka.   

Abstract

The present overview covers various aspects of research going on in the Cannabis field in the Department of Natural Products at the Hebrew University. In the first part we discuss, and try to explain, the reason for the absence of the term Cannabis (and possibly also opium) in the Old Testament. In the second part we bring evidence that, contrary to widely held views, stereospecificity of cannabinoid action is extremely high, and in certain cases almost absolute. Previous results seem to have been due to impurities in the samples tested. (+)-Delta-1-THC, (+)-delta-6-THC and (+)-7-hydroxy-delta-6-THC, when purified sufficiently, exhibit activity of about 1% of that of the natural (-) enantiomers. A new labelled cannabinoid ligand has been prepared by catalytic reduction of (-)-7-hydroxy-delta-6-THC dimethylheptyl. The equatorial C-1 epimer obtained binds to the cannabinoid receptor with a KI of 40 pM. This compound is one of the most active cannabinoids tested so far for binding to the canabinoid receptor, and may become an important tool in cannabinoid research.

Entities:  

Mesh:

Year:  1991        PMID: 1806938     DOI: 10.1016/0091-3057(91)90347-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice.

Authors:  Travis W Grim; Jason M Wiebelhaus; Anthony J Morales; S Stevens Negus; Aron H Lichtman
Journal:  Drug Alcohol Depend       Date:  2015-01-29       Impact factor: 4.492

Review 2.  The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease.

Authors:  Nicola Barrie; Nicholas Manolios
Journal:  Eur J Rheumatol       Date:  2017-09-01

3.  Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.

Authors:  Guy A Cabral; Thomas J Rogers; Aron H Lichtman
Journal:  J Neuroimmune Pharmacol       Date:  2015-06-09       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.